Across TCGA pan-cancer cohorts, FAM180B RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated FAM180B data layer compared with 2 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher FAM180B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM180B expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCS show a favorable association.
KIRC, HNSC, and UCS are the cancer types where FAM180B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.